Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation

Table 2 Demographic and clinical characteristics of children according to donor hepatitis B core antibody status

Characteristic	HBcAb(+) donor(n = 16)	HBcAb(-) donor(n = 14)	P value
Donors
Gender (n, M/F)	7/9	9/5	0.261
Age (yr)	35 (20-55)	32 (22-54)	0.884
HBsAb (+/-)	14/2	9/5	0.134
Recipients
Age (mo)	11 (7-43)	12 (6-57)	0.787
Gender (n, M/F)	9/7	8/6	0.981
PELD score	16 ± 3	17 ± 4	0.378
Preoperative HBcAb (n, +/-)	11/5	5/9	0.070
Preoperative HBsAb (n, +/-)	11/5	7/7	0.300
Preoperative HBsAb/HBcAb (n, +/-)	9/7	3/11	0.052
Blood transfusion
RBC (mL)	502 ± 284	534 ± 224	0.379
FFP (mL)	404 ± 177	424 ± 210	0.753
Dose of corticosteroid/body weight (mg/kg)	44 ± 7	42 ± 8	0.359
Trough value of TAC
First 3 mo (ng/mL)	8.1 ± 5.6	7.8 ± 4.6	0.789
3 mo later (ng/mL)	6.7 ± 3.2	6.4 ± 2.3	0.661
Follow-up (mo)	15 (4-40)	16 (14-30)	0.228
De novo HBV infection (n, +/-)	5/11	0/14	0.022

M/F: Male/female; HBV: Hepatitis B virus; PELD: Pediatric model of end-stage liver disease; HBcAb: Hepatitis B core antibody; HBsAb: Hepatitis B surface antibody; RBC: Red blood cell; FFP: Fresh frozen plasma.